Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.
logo-115

Asia Pacific Electric 3-Wheeler Market (2022 to 2027) – Stringent Emission Norms and Environmental Regulations Present Opportunities – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Electric 3-Wheeler Market by End-use (Passenger & Load), Range (Up to 50 Miles & Above 50...

logo-113

Induction Furnace Market in India 2022-2025: Increasing Business Confidence Within Furnace Industry and the Focus on Technology Upgrades Driving Growth – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Induction Furnace Market in India 2021-2025" report has been added to ResearchAndMarkets.com's offering. The induction furnace market in...

Datasea-Inc-

Datasea’s Ultrasonic Sound Sterilization and Antivirus Equipment Confirmed by Leading Lab Achieved a 99.83% Efficacy in Nine Seconds Against Covid-19

BEIJING, July 21, 2022 (GLOBE NEWSWIRE) -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), incorporated in Nevada on September...

Malaysia_National_Stadium_in_Kuala_Lampur_Sports_City

ASM Global’s Asia Pacific Presence Expands With Announcement of Strategic Partnership With Malaysian Government for Kuala Lumpur Sports City Management

Largest Such Complex in Region Massive 87,400-Seat Malaysia National Stadium—Largest in Asia Outside North Korea—and 16,000-Seat Axiata Arena Join ASM...

BIO-key-International-Inc-1-4

Long Island University Reinvests in BIO-key’s PortalGuard Identity and Access Management Platform to Address Security Requirements at Multiple Campuses

BROOKVILLE, N.Y. and WALL, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of...

3472696_BrandSymbol_Dakiyama_Rd

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)